Teva Pharmaceutical Industries Limited (TEVA) belonging to the Healthcare sector has declined -2.7% and closed its last trading session at $13.32.
The company reported its EPS on 6/29/2017. Currently, the stock has a 1 Year Price Target of $20.02.
The consensus recommendation, according to Zacks Investment research, is 2.97. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 2.97 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.96 and 2.4 respectively.
Teva Pharmaceutical Industries Limited on 6/29/2017 reported its EPS as $1.31 with the analysts projecting the EPS of the stock as $1.28. The company beat the analyst EPS Estimate with the difference of $0.03. This shows a surprise factor of 0.023%.
Many analysts have provided their estimated foresights on Teva Pharmaceutical Industries Limited Earnings, with 22 analysts believing the company would generate an Average Estimate of $1.05.
Whereas they predicted High and Low Earnings Estimate as $1.19 and $0.94 respectively. While in the same Quarter Previous year, the Actual EPS was $1.31.
Analysts are also projecting an Average Revenue Estimate for Teva Pharmaceutical Industries Limited as $5.62 Million in the Current Quarter. This estimate is provided by 20 analysts.
The High Revenue estimate is predicted as 5.76 Million, while the Low Revenue Estimate prediction stands at 5.52 Million. The company’s last year sales total was 5.56 Million.
For the Current Quarter, the growth estimate for Teva Pharmaceutical Industries Limited is -19.8%, while for the Next Quarter the stock growth estimate is -21%.
In the past 5 years, the stock showed growth of -1.21% per annum. While for the next 5 years, the growth estimate is -6.9%.
Teva Pharmaceutical Industries Limited (TEVA) has the market capitalization of $14.04 Billion. The company rocked its 52-Week High of $44.13 and touched its 52-Week Low of $13.26.
The stock has Return on Assets (ROA) of -6.7 percent. Return on Equity (ROE) stands at -21.2% and Return on Investment (ROI) of 1.1 percent.
The stock is currently showing YTD performance of -63.26 Percent. The company has Beta Value of 0.55 and ATR value of 0.58. The Weekly and Monthly Volatility stands at 3.55% and 3.66%.